Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 393

Results For "Mark"

5362 News Found

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr
News | August 12, 2022

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.


AI to shape future outcomes in cardiovascular care, says GlobalData
Digitisation | August 11, 2022

AI to shape future outcomes in cardiovascular care, says GlobalData

AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.


Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%
News | August 10, 2022

Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%

EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%


Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust
Healthcare | August 10, 2022

Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust

The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days


Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
News | August 09, 2022

Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher

Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.


JB Pharma records revenue growth of 30% in Q1 FY23
News | August 09, 2022

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23


ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
Drug Approval | August 09, 2022

ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy


Ube to buy API Corp. from Mitsubishi Chemical
News | August 09, 2022

Ube to buy API Corp. from Mitsubishi Chemical

APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years


L&T donates a bus to Sankara Eye Hospital for their outreach programme
Healthcare | August 08, 2022

L&T donates a bus to Sankara Eye Hospital for their outreach programme

The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.